Company

Genkyotex SA

Headquarters: Labège, France

Employees: 9

CEO: Mr. Ilias Papatheodorou

Euronext: GKTX +0.16%

Market Cap

€45.1 Million

EUR as of Sept. 1, 2021

US$53.6 Million

Market Cap History

Genkyotex SA market capitalization over time

Evolution of Genkyotex SA market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Genkyotex SA

Detailed Description

Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Labège, France.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Genkyotex SA has the following listings and related stock indices.


Stock: Euronext: GKTX wb_incandescent

Stock: FSX: G061 wb_incandescent

Details

Headquarters:

516 Rue Pierre et Marie Curie

Labège, 31670

France

Phone: 33 5 61 28 70 60